massive for research too?

. The decay of its genome mirrors an unfortunate collapse in interest in leprosy research, while disease incidence stays stubbornly high.

Written byRobert Walgate
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

LONDON "Scientifically it's a fantastic achievement. In terms of what we will know about what it takes to become an intracellular pathogen, it's the biggest achievement for decades," said Jo Colston, Head of Mycobacterial Research at the UK's National Institute for Medical Research, in response to the publication of the genome of Mycobacterium leprae in 22 February Nature.

But at the end of 1999, the World Health Organisation (WHO) extended its deadline for the "elimination" of leprosy — meaning a reduction in the number of known cases to 1 in 10,000 within affected communities — from 2000 to 2005. The original deadline had been set in 1991 and a decade of 'elimination' strategies has led to a collapse in research funding for the disease. The European Commission, for example, awarded its last grant for leprosy research five years ago. Most mycobacterial researchers have sensibly moved over to studying tuberculosis.

This ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies